dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· July 29, 2026

Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy?

View original at nasdaq.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? Key Points Qualcomm reports fiscal third-quarter results after the market closes on Wednesday, July 29…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The consensus analyst rating on Qualcomm is hold, with an average price target of $221.23, about 36% above the current price of $162.88.

    60% confidence
  • A custom silicon engagement with a leading hyperscaler remains on track for initial shipments later this calendar year.

    60% confidence
  • Qualcomm expects handset revenue from Chinese customers to bottom in the fiscal Q3 quarter and return to sequential growth in the following quarter.

    60% confidence
  • Qualcomm delivered results in line with guidance, reflecting solid execution navigating a challenging memory environment.

    60% confidence
  • The author would rather wait for more information before buying Qualcomm stock, even at the risk of missing a rebound.

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · stock price162.88 USD
Qualcomm Incorporated · market share221.23 USD
Qualcomm Incorporated · cash3.7 USD
Qualcomm Incorporated · margin72 percent
Qualcomm Incorporated · eps2.65 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy?: Source | Via News | fr.via.news